These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 15515006)

  • 1. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.
    Horowski R; Jähnichen S; Pertz HH
    Mov Disord; 2004 Dec; 19(12):1523-4. PubMed ID: 15515006
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
    van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminagonists and fibrotic valvular heart disease: further considerations.
    Rascol O; Pathak A; Bagheri H; Montastruc JL
    Mov Disord; 2004 Dec; 19(12):1524-5. PubMed ID: 15515031
    [No Abstract]   [Full Text] [Related]  

  • 4. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide.
    Chung EJ; Yoon WT; Kim JY; Lee WY
    Mov Disord; 2006 Apr; 21(4):586-7. PubMed ID: 16482572
    [No Abstract]   [Full Text] [Related]  

  • 5. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
    Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
    J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonists and valvular heart disease.
    Linkova H; Ruzicka E; Penicka M
    N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17447279
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
    Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonist therapy and cardiac valve dysfunction.
    Sherlock M; Steeds R; Toogood AA
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):643-4. PubMed ID: 17645575
    [No Abstract]   [Full Text] [Related]  

  • 14. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine use and the risk of valvular heart disease.
    Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
    Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic receptors for dopamine, histamine, and serotonin.
    Feuerstein TJ
    Handb Exp Pharmacol; 2008; (184):289-338. PubMed ID: 18064418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide (Celance)--a third dopamine agonist.
    Drug Ther Bull; 1991 Sep; 29(20):79. PubMed ID: 1935593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.